Education
About Us
Working with TipRanks
Follow Us
Omega Therapeutics, Inc. (OMGA)
NASDAQ:OMGA
Total Valuation
Omega Therapeutics has a market cap or net worth of $8.85M. The enterprise value is $164.71M.
Market Cap$8.85M
Enterprise Value$164.71M
Share Statistics
Omega Therapeutics has 55,366,215 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding55,366,215
Owned by Insiders1.33%
Owned by Institutions66.34%
Financial Efficiency
Omega Therapeutics’s return on equity (ROE) is -1.68 and return on invested capital (ROIC) is -51.99%.
Return on Equity (ROE)-1.68
Return on Assets (ROA)-0.48
Return on Invested Capital (ROIC)-51.99%
Return on Capital Employed (ROCE)-0.56
Revenue Per Employee32.91K
Profits Per Employee-1.04M
Employee Count94
Asset Turnover0.02
Inventory Turnover217.39
Valuation Ratios
The current PE Ratio of Omega Therapeutics is -1.67. Omega Therapeutics’s PEG ratio is 0.11.
PE Ratio-1.67
PS Ratio1.09
PB Ratio2.80
Price to Fair Value2.80
Price to FCF-1.72
Price to Operating Cash Flow-1.78
PEG Ratio0.11
Income Statement
In the last 12 months, Omega Therapeutics had revenue of 3.09M and earned -97.43M in profits. Earnings per share was -1.80.
Revenue3.09M
Gross Profit-62.77M
Operating Income-100.26M
Pretax Income-97.43M
Net Income-97.43M
EBITDA-93.49M
Earnings Per Share (EPS)-1.80
Cash Flow
In the last 12 months, operating cash flow was -55.58M and capital expenditures -2.06M, giving a free cash flow of -57.64M billion.
Operating Cash Flow-55.58M
Free Cash Flow-57.64M
Free Cash Flow per Share-1.04
Dividends & Yields
Omega Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.13
52-Week Price Change-99.56%
50-Day Moving Average0.47
200-Day Moving Average1.25
Relative Strength Index (RSI)26.11
Average Volume (3m)17.55M
Important Dates
Omega Therapeutics upcoming earnings date is Mar 6, 2025, TBA Not Confirmed.
Last Earnings DateNov 14, 2024
Next Earnings DateMar 6, 2025
Ex-Dividend Date―
Financial Position
Omega Therapeutics as a current ratio of 3.35, with Debt / Equity ratio of 1110.05%
Current Ratio3.35
Quick Ratio3.34
Debt to Market Cap0.12
Net Debt to EBITDA-0.64
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Omega Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Omega Therapeutics EV to EBITDA ratio is -2.38, with an EV/FCF ratio of -2.36.
EV to Sales71.93
EV to EBITDA-2.38
EV to Free Cash Flow-2.36
EV to Operating Cash Flow-2.43
Balance Sheet
Omega Therapeutics has $30.38M in cash and marketable securities with $0.00 in debt, giving a net cash position of $97.76M billion.
Cash & Marketable Securities$30.38M
Total Debt$0.00
Net Cash$97.76M
Net Cash Per Share$1.77
Tangible Book Value Per Share$1.07
Margins
Gross margin is -59.81%, with operating margin of -3240.50%, and net profit margin of -3148.93%.
Gross Margin-59.81%
Operating Margin-3240.50%
Pretax Margin-3148.93%
Net Profit Margin-3148.93%
EBITDA Margin-3021.65%
EBIT Margin-3240.50%
Analyst Forecast
The average price target for Omega Therapeutics is $4.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$4.00
Price Target Upside2252.94% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast184.93%
EPS Growth Forecast36.45%